In: NEOPLASMA, vol. 51, no. 5
V. Maisnar - K. Chroust
Detaily:
Rok, strany: 2004, 379 - 384
O článku:
The communication is summarizing results of study aimed to
ascertain the efficacy of treatment with epoetin alpha in patients
with different hematological disorders and, at the same time to
evaluate the impact of this treatment on quality of their lives.
Treatment efficacy in separate patients of the monitored
population has been evaluated not only according to hemoglobin
level increase, but also according to its effect on erythrocyte
products consumption needed to control anemic syndrome. Overall
134 patients with different lymphoproliferative disorders were
included in the evaluation. Full-extended monitoring, i.e. at
least 3-month treatment with epoetin alpha, was passed by 127
(94.8%) patients. Favorable effect of epoetin alpha administration
was most often reported in patients with multiple myeloma (85.7%),
Waldenström´s macroglobulinemia (80%) and chronic lymphatic
leukemia (76.7%). Conversely the lowest efficacy was reported in
the group of patients with myelodysplastic syndrome.
Administration of epoetin alpha within treatment of underlying
anemia in numerous hematological disorders represents suitable
alternative to the substitution therapy via erythrocyte
transfusions. Approximately 75% of monitored patients showed
improvement of life quality, in some cases irrespective of results
of treatment of their underlying disorder.
Ako citovať:
ISO 690:
Maisnar, V., Chroust, K. 2004. Treatment of associated anemia in different hematological
disorders with epoetin alpha. In NEOPLASMA, vol. 51, no.5, pp. 379-384. 0028-2685.
APA:
Maisnar, V., Chroust, K. (2004). Treatment of associated anemia in different hematological
disorders with epoetin alpha. NEOPLASMA, 51(5), 379-384. 0028-2685.